78. Hypopituitarism Clinical trials / Disease details
Clinical trials : 494 / Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02311894 (ClinicalTrials.gov) | March 31, 2015 | 4/12/2014 | A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency | A Phase IV, Multicenter, Open-Label Study of the Immunogenicity of Nutropin AQ® V1.1 [Somatropin (rDNA Origin) Injection] Administered Daily to Naïve Growth Hormone-Deficient Children (iSTUDY) | Growth Hormone Deficiency | Drug: Somatropin | Genentech, Inc. | NULL | Completed | 3 Years | 14 Years | All | 82 | Phase 4 | United States |
| 2 | NCT01243892 (ClinicalTrials.gov) | November 2010 | 17/11/2010 | A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device | A Phase IV, Open Label, Multicenter, Case-controlled Study of Growth in Patients Using the Nutropin AQ® Nuspin® | Growth Hormone Deficiency | Device: NuSpin;Drug: Somatropin | Genentech, Inc. | NULL | Terminated | 2 Years | 14 Years | All | 18 | Phase 4 | United States |
| 3 | EUCTR2010-019735-35-FR (EUCTR) | 14/06/2010 | 30/04/2010 | Effets du traitement substitutif par hormone de croissance chez les patients présentant un déficit somatotrope sévère secondaire à un traumatisme crânien | Effets du traitement substitutif par hormone de croissance chez les patients présentant un déficit somatotrope sévère secondaire à un traumatisme crânien | Déficit somatotrope de l'adulte consécutif à un traumatisme crânien MedDRA version: 12.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Trade Name: Nutropin Aq Product Name: NutropinAq | CHU Amiens | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| 4 | NCT00837863 (ClinicalTrials.gov) | March 2009 | 2/2/2009 | Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency | A Twelve Month, Phase II, Randomized, Open-Label, Multi-Center, Dose-Ranging Study of Weekly ALTU-238 (Somatropin) as Compared With Daily Nutropin AQ (Somatropin) in Prepubertal Children With Growth Hormone Deficiency | Growth Hormone Deficiency | Drug: Somatropin | Altus Pharmaceuticals | NULL | Recruiting | 3 Years | 13 Years | Both | 36 | Phase 2 | United States |
| 5 | NCT00212758 (ClinicalTrials.gov) | January 2005 | 14/9/2005 | A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood | IGF-1 Generation Test in Children With Chronic Kidney Disease | Kidney Failure, Chronic;Growth Hormone Deficiency | Drug: Nutropin AQ | Oregon Health and Science University | Genentech, Inc. | Completed | 2 Years | 18 Years | All | 17 | Phase 4 | United States |
| 6 | NCT00140413 (ClinicalTrials.gov) | December 2004 | 31/8/2005 | Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia | Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia | Growth Hormone Deficiency;Septo-Optic Dysplasia;Hypopituitarism | Drug: Nutropin AQ | Children's Hospital Los Angeles | Genentech, Inc. | Completed | N/A | 5 Years | All | 20 | Phase 4 | United States |
| 7 | NCT00134420 (ClinicalTrials.gov) | February 2001 | 22/8/2005 | Growth Hormone and Chromosome 18q- and Abnormal Growth | Growth Hormone Trial for Children With 18q- and Abnormal Growth | Loss of Chromosome 18q;Growth Hormone Deficiency | Drug: Nutropin AQ;Procedure: Arginine and Clonidine Stimulation Testing;Procedure: Growth Factors Laboratory Testing;Procedure: Neuropsychological Testing | The University of Texas Health Science Center at San Antonio | South Texas Veterans Health Care System;Genentech, Inc. | Completed | N/A | 18 Years | Both | 20 | Phase 3 | United States |